

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3101049

| | |
|------------------------------|-------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | SECURITY INTEREST |

CONVEYING PARTY DATA

| Name | Execution Date |
|-----------------------------|----------------|
| INTERSPACE DIAGNOSTICS, LLC | 10/31/2014 |
| JS GENETICS, INC. | 10/31/2014 |
| GROUP DCA, LLC | 10/31/2014 |
| PDI, INC. | 10/31/2014 |

RECEIVING PARTY DATA

| | |
|--------------------------|--|
| Name: | REDPATH EQUITYHOLDER REPRESENTATIVE, LLC |
| Street Address: | 555 LANCASTER AVENUE, SUITE 444 |
| Internal Address: | RADNOR FINANCIAL CENTER |
| City: | RADNOR |
| State/Country: | PENNSYLVANIA |
| Postal Code: | 19087 |

PROPERTY NUMBERS Total: 12

| Property Type | Number |
|---------------------|-----------|
| Application Number: | 11857948 |
| Application Number: | 13299226 |
| Application Number: | 13615066 |
| Application Number: | 13662450 |
| Application Number: | 13801737 |
| Application Number: | 13436259 |
| Application Number: | 13266434 |
| Application Number: | 13266429 |
| PCT Number: | US1161237 |
| PCT Number: | US1262330 |
| PCT Number: | US1330990 |
| PCT Number: | US1334670 |

CORRESPONDENCE DATA

Fax Number: (412)562-1041

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 412-562-1637

PATENT

Email: vicki.cremonese@bipc.com
Correspondent Name: MICHAEL L. DEVER
Address Line 1: 301 GRANT STREET
Address Line 2: 20TH FLOOR
Address Line 4: PITTSBURGH, PENNSYLVANIA 15219

| | |
|--------------------------------|----------------|
| ATTORNEY DOCKET NUMBER: | 0076838-000006 |
|--------------------------------|----------------|

| | |
|---------------------------|------------------|
| NAME OF SUBMITTER: | MICHAEL L. DEVER |
|---------------------------|------------------|

| | |
|-------------------|--------------------|
| SIGNATURE: | /Michael L. Dever/ |
|-------------------|--------------------|

| | |
|---------------------|------------|
| DATE SIGNED: | 11/10/2014 |
|---------------------|------------|

Total Attachments: 12

source=redpath-interspace diagnostics security agreement 10-31-14#page1.tif
source=redpath-interspace diagnostics security agreement 10-31-14#page2.tif
source=redpath-interspace diagnostics security agreement 10-31-14#page3.tif
source=redpath-interspace diagnostics security agreement 10-31-14#page4.tif
source=redpath-interspace diagnostics security agreement 10-31-14#page5.tif
source=redpath-interspace diagnostics security agreement 10-31-14#page6.tif
source=redpath-interspace diagnostics security agreement 10-31-14#page7.tif
source=redpath-interspace diagnostics security agreement 10-31-14#page8.tif
source=redpath-interspace diagnostics security agreement 10-31-14#page9.tif
source=redpath-interspace diagnostics security agreement 10-31-14#page10.tif
source=redpath-interspace diagnostics security agreement 10-31-14#page11.tif
source=redpath-interspace diagnostics security agreement 10-31-14#page12.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT, dated as of October 31, 2014 (as may be amended, restated, supplemented, or otherwise modified from time to time, this "**Agreement**"), made by Interpace Diagnostics, LLC, a Delaware limited liability company, JS Genetics, Inc., a Delaware corporation, Group DCA, LLC, a Delaware limited liability company, and PDI, INC., a Delaware corporation (each a "**Grantor**" and collectively the "**Grantors**"), in favor of REDPATH EQUITYHOLDER REPRESENTATIVE, LLC ("**Lender**").

WITNESSETH:

WHEREAS, pursuant to that certain Non-Negotiable Subordinated Secured Promissory Note, dated on or about the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the "**Note**"), issued by PDI, INC., a Delaware corporation and Interpace Diagnostics, LLC, a Delaware limited liability company (collectively, the "**Borrowers**"), to Lender, Lender agreed to make certain financial accommodations available to Borrowers, and Borrowers have granted a security interest to Lender, in, among other things, all right, title and interest of Borrowers in, to and under all of Borrowers' Intellectual Property (as defined below), whether now existing or hereafter arising or acquired as security for the Secured Obligations;

WHEREAS, the Borrowers are affiliated with each Grantor. The Borrowers and the other Grantors are engaged in interrelated businesses, and each Grantor will derive substantial direct and indirect benefit from extensions of credit under the Note; and

WHEREAS, Each Grantor is the owner of the entire right, title and interest in, to and under the Intellectual Property listed on Schedule I hereto as applicable.

NOW, THEREFORE, in consideration of the premises and to induce Lender to enter into the Note and the Loan Documents, each Grantor hereby agrees with Lender as follows:

1. Defined Terms.

(a) Definitions. Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement, including its preamble and recitals, have the meanings provided in the Guaranty Agreement (as defined below).

(b) Definitions of Certain Terms Used Herein. As used herein, the following terms shall have the following meanings:

"**Copyrights**" shall mean all of each Grantor's (or if referring to another Person, such other Person's) now existing or hereafter acquired right, title, and interest in and to: (i) copyrights, rights and interests in copyrights, works protectable by copyright, all applications, registrations and recordings relating to the foregoing as may at any time be filed in the United States Copyright Office or in any similar office or agency of the United States, any State thereof, any political subdivision thereof or in any other country, and all research and development relating to the foregoing; and (ii) all renewals of any of the foregoing.

"**Copyright Licenses**" shall mean all written agreements naming any Grantor as licensor or licensee, granting any right under any Copyright, including the grant of rights to manufacture, distribute, exploit and sell materials derived from any Copyright (other than agreements relating to widely-available software subject to "shrink-wrap" or "click-through" software licenses).

"Guaranty Agreement" shall mean that certain Guarantee and Collateral Agreement dated as of October 31, 2014 among [the various Grantors party thereto] and Lender, together with all amendments, modifications or restatements thereof.

"Intellectual Property" shall mean all present and future: trade secrets, know-how and other proprietary information; Trademarks, internet domain names, service marks, trade dress, trade names, business names, designs, logos, slogans (and all translations, adaptations, derivations and combinations of the foregoing) indicia and other source and/or business identifiers, and the goodwill of the business relating thereto and all registrations or applications for registrations which have heretofore been or may hereafter be issued thereon throughout the world; Copyrights (including Copyrights for computer programs, but excluding commercially available off-the-shelf software and any Intellectual Property rights relating thereto) and all tangible and intangible property embodying the Copyrights, unpatented inventions (whether or not patentable); Patents; industrial design applications and registered industrial designs; license agreements related to any of the foregoing and income therefrom, books, records, writings, computer tapes or disks, flow diagrams, specification sheets, computer software, source codes, object codes, executable code, data, databases and other physical manifestations, embodiments or incorporations of any of the foregoing; the right to sue for all past, present and future infringements of any of the foregoing; all other intellectual property; and all common law and other rights throughout the world in and to all of the foregoing.

"IP Collateral" shall have the meaning assigned to such term in Section 2 hereof.

"Licenses" shall mean, collectively, the Trademark Licenses, the Patent Licenses, and the Copyright Licenses.

"Patents" shall mean all of each Grantor's (or if referring to another Person, such other Person's) now existing or hereafter acquired right, title and interest in and to: (i) all patents, patent applications, inventions, invention disclosures and improvements, and all applications, registrations and recordings relating to the foregoing as may at any time be filed in the United States Patent and Trademark Office or in any similar office or agency of the United States, any state thereof, any political subdivision thereof or in any other country, and all research and development relating to the foregoing; and (ii) the reissues, divisions, continuations, renewals, extensions and continuations-in-part of any of the foregoing.

"Patent Licenses" shall mean all agreements, whether written or oral, providing for the grant by or to any Grantor of any right to manufacture, develop, market, use or sell any products derived, in whole or in part, from any invention covered by a Patent or any similar agreement related to any other use of any invention covered by a Patent.

"Trademarks" shall mean all of each Grantor's (or if referring to another Person, such other Person's) now existing or hereafter acquired right, title, and interest in and to: (i) all of each Grantor's (or if referring to another Person, such other Person's) trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, service marks, logos, other business identifiers, all applications, registrations and recordings relating to the foregoing as may at any time be filed in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof, any political subdivision thereof or in any other country, and all research and development relating to the foregoing; (ii) all renewals thereof; and (iii) all designs and general intangibles of a like nature.

"**Trademark Licenses**" shall mean, collectively, each agreement, whether written or oral, providing for the grant by or to any Grantor of any right to use any Trademark.

(c) **Other Definitional Provisions.**

(i) The words "hereof," "herein" and "hereunder" and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement, and section and paragraph references are to this Agreement unless otherwise specified.

(ii) The meanings given to terms defined herein shall be equally applicable to both the singular and plural forms of such terms.

2. **Grant of Security Interest.** To secure the payment and performance of the Obligations, each Grantor hereby confirms and acknowledges that it has granted (and, to the extent not previously granted under the Guarantee and Collateral Agreement, does hereby grant) to Lender, a lien and security interest in such Grantor's entire right, title and interest in its Intellectual Property and all proprietary rights relating to or arising from such Intellectual Property, in each case whether now owned or hereafter acquired by such Grantor, and including, without limitation, such Grantor's right, title and interest in and to the Intellectual Property and proprietary rights identified on Schedule I attached hereto and made a part hereof, and the right to sue for past, present and future infringements and dilutions, and all rights corresponding thereto throughout the world, and the entire goodwill of such Grantor's business connected with and symbolized by such Intellectual Property and all income, fees, royalties, proceeds and other payments at any time due or payable with respect to any of the foregoing (referred to collectively as the "**IP Collateral**"); provided, that the IP Collateral shall not include the Excluded Property (as defined in the Guarantee Agreement).

3. **Protection of Intellectual Property by Grantors.** Each Grantor shall, at its sole cost, expense and risk, in connection with the operation of its business, comply with the requirements set forth in Section 5.7 of the Guarantee and Collateral Agreement in respect to the Intellectual Property.

4. **Representations and Warranties.** Each Grantor represents and warrants that:

(a) Schedule I is a true, correct and complete list of all registered or applied-for Intellectual Property in which such Grantor purports to have an ownership or license interest.

(b) Such Grantor has the legal right and authority to enter into this Agreement and perform its terms.

(c) If such Grantor amends its name, such Grantor shall provide copies of such amendment documentation to Lender and shall re-register such Grantor's Intellectual Property with the appropriate Governmental Authority and shall execute and deliver such agreements or documentation as Lender shall request to maintain a perfected first priority security interest in such Intellectual Property subject to Permitted Liens.

5. **No Violation.** The representations, warranties or covenants contained herein are supplemental to those representations, warranties and covenants contained in the other Loan Documents, and shall not be deemed to modify any such representation, warranty or covenant contained in any other Loan Document.

6. Agreement Applies to Future Intellectual Property.

(a) The provisions of this Agreement shall automatically apply to any such additional property or rights described in Section 2 above, all of which shall be deemed to be and treated as "IP Collateral" within the meaning of this Agreement.

(b) Upon the request of Lender, each Grantor shall execute and deliver, and have recorded, any and all agreements, instruments, documents and papers as Lender may reasonably request to evidence Lender's security interest in any IP Collateral and the goodwill of any Grantor relating thereto or represented thereby (including, without limitation, filings with the United States Patent and Trademark Office or any similar office), and each Grantor hereby constitutes Lender as its attorney-in-fact to execute and file all such writings for the foregoing purposes, all acts of such attorney being hereby ratified and confirmed; provided, however, that Lender's taking of such action shall not be a condition to the creation or perfection of the security interest created hereby.

7. Grantors' Rights to Enforce Intellectual Property. Prior to Lender's giving of notice to Grantors following the occurrence and during the continuance of an Event of Default, Grantors shall have the exclusive right to sue for past, present and future infringement of the IP Collateral, including the right to seek injunctions and/or money damages, in an effort by Grantors to protect the IP Collateral against encroachment by third parties, provided, however, that:

(a) Any money damages awarded or received by Grantors on account of such suit (or the threat of such suit) shall constitute IP Collateral.

(b) Any damages recovered in any action pursuant to this Section, net of costs and attorneys' fees reasonably incurred, shall be applied to repayment of the Obligations.

(c) Following the occurrence and during the continuance of any Event of Default, Lender, by notice to any Grantor may terminate or limit such Grantor's rights under this Section 7.

8. Lender's Actions to Protect Intellectual Property. Lender, acting in its own name or in that of any Grantor, may (but shall not be required to) act in such Grantor's place and stead and/or in Lender's own right with respect to the rights and obligations of such Grantor under Section 3, Section 6 and Section 7 hereof.

9. Rights Upon Default. Upon the occurrence and during the continuance of any Event of Default, Lender may exercise all rights and remedies as provided for in the Note or the Guaranty Agreement.

10. Lender as Attorney In Fact.

(a) Each Grantor hereby irrevocably constitutes and designates Lender as its attorney-in-fact to:

(i) Following the occurrence and during the continuance of an Event of Default, supplement and amend from time to time Schedule I of this Agreement to include any new or additional Intellectual Property of such Grantor.

(ii) Exercise any of the rights and powers referenced herein in accordance with this Agreement.

- (b) The grant of a power of attorney, being coupled with an interest, shall be irrevocable until the Obligations are paid in full.
- (c) Lender shall not be obligated to do any of the acts or to exercise any of the powers authorized by Section 8, Section 9 or Section 10 of this Agreement, but if Lender elects to do any such act or to exercise any of such powers, it shall not be accountable for more than it actually receives as a result of such exercise of power, and shall not be responsible to any Grantor for any act or omission to act, except to the extent Lender acted with gross negligence or willful misconduct as determined by a court of competent jurisdiction.

11. **Lender's Rights.** Upon an Event of Default and during the continuance thereof, any use by Lender of the IP Collateral, as authorized hereunder in connection with the exercise of Lender's rights and remedies under this Agreement, the Guaranty Agreement or any Loan Document shall be coextensive with Grantors' rights thereunder and with respect thereto and without any liability for royalties or other related charges.

12. **No Limitation; Loan Documents.** This Agreement has been executed and delivered by each Grantor for the purpose of recording the security interest granted to Lender with respect to the IP Collateral with the United States Patent and Trademark Office, the United States Copyright Office, as well as with any similar office or department of any other foreign or domestic Governmental Authority. The security interest granted hereby has been granted as a supplement to, and not in limitation of, the security interest granted to Lender, under the Guarantee and Collateral Agreement and the other Loan Documents. The Loan Documents (and all rights and remedies of Grantors, and Lender thereunder) shall remain in full force and effect in accordance with their terms.

13. **Termination; Release of Trademark Collateral.** This Agreement and all obligations of each Grantor and Lender hereunder shall terminate on the date upon which the Obligations are performed in full and paid in full. Upon termination of this Agreement, Lender shall, at the expense of the Grantors, take such actions required by the Guarantee Agreement or as otherwise reasonably requested by Grantors to release its security interest in the IP Collateral.

14. **Binding Effect; Benefits.** This Agreement shall be binding upon each Grantor and its successors and assigns, and shall inure to the benefit of Lender and their respective successors and assigns.

15. **GOVERNING LAW.**

THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF DELAWARE WITHOUT GIVING EFFECT TO ITS CHOICE OF LAW PROVISIONS THAT WOULD REQUIRE THE APPLICATION OF THE LAWS OF ANY OTHER JURISDICTION.

16. **Copy of Agreement.** Each Grantor acknowledges receipt of a signed copy of this Agreement.

[Remainder of page intentionally blank; signature page follows.]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be executed by its duly authorized representatives as of the date first above written.

GRANTORS:

PDI, INC.,
a Delaware corporation

By: Nancy S. Lurker
Name: Nancy S. Lurker
Title: Chief Executive Officer

GROUP DCA, LLC,
a Delaware limited liability company

By: Nancy S. Lurker
Name: Nancy S. Lurker
Title: Chief Executive Officer

INTERPACE DIAGNOSTICS, LLC,
a Delaware limited liability company

By: Nancy S. Lurker
Name: Nancy S. Lurker
Title: Chief Executive Officer

JS GENETICS, INC.,
a Delaware corporation


By: Nancy S. Lurker
Name: Nancy S. Lurker
Title: Chief Executive Officer

[Signature Page to Intellectual Property Security Agreement]

LENDER:

**REDPATH EQUITYHOLDER
REPRESENTATIVE, LLC,**
a Delaware limited liability company

By: Commerce Health Ventures, L.P., its
Member

By: 
Name: Brian G. Murphy
Title: General Partner

INTELLECTUAL PROPERTY

Licenses

Copyrights

none

Patents

U.S. cases:

| Owner | App. No. Patent No. | Filing Date Issue Date | Title | Country |
|-----------------------|------------------------|---------------------------|---|---------|
| Interpace Diagnostics | 60/826,173 NA | 09/19/2006 NA | MicroRNAs Differentially Expressed in Pancreatic Disease and Uses Thereof | US |
| Interpace Diagnostics | 11/857,948 NA | 9/19/2007 NA | MicroRNAs Differentially Expressed in Pancreatic Disease and Uses Thereof | US |
| Interpace Diagnostics | 61/414,778 NA | 11/17/2010 NA | MiRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms | US |
| Interpace Diagnostics | 13/299,226 NA | 11/17/2011 NA | MiRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms | US |
| Interpace Diagnostics | 61/534,332 NA | 09/13/2011 NA | Methods and Compositions Involving miR-135B for Distinguishing Pancreatic Cancer from Benign Pancreatic Disease | US |
| Interpace Diagnostics | 61/536,486 NA | 09/19/2011 NA | Methods and Compositions Involving miR-135B for Distinguishing Pancreatic Cancer from Benign Pancreatic Disease | US |
| Interpace Diagnostics | 13/615,066 NA | 9/13/2012 NA | Methods and Compositions Involving miR-135B for Distinguishing Pancreatic Cancer from Benign Pancreatic Disease | US |
| Interpace Diagnostics | 61/552,451 NA | 10/27/2011 NA | miRNAs as Diagnostic Biomarkers to Distinguish Benign from Malignant Thyroid Tumors | US |
| Interpace Diagnostics | 61/552,762 NA | 10/27/2011 NA | miRNAs as Diagnostic Biomarkers to Distinguish Benign from Malignant Thyroid Tumors | US |
| Interpace Diagnostics | 13/662,450 NA | 10/27/2012 NA | miRNAs as Diagnostic Biomarkers to Distinguish Benign from Malignant Thyroid Tumors | US |
| Interpace Diagnostics | 61/709,411 NA | 10/04/2012 NA | Diagnostic mirnas for Differential Diagnosis of Incidental Pancreatic Cystic Lesions | US |
| Interpace Diagnostics | 61/716,396 NA | 10/19/2012 NA | Diagnostic mirnas for Differential Diagnosis of Incidental Pancreatic Cystic Lesions | US |
| Interpace Diagnostics | 13/801,737 NA | 3/13/2013 NA | Diagnostic mirnas for Differential Diagnosis of Incidental Pancreatic Cystic Lesions | US |
| PDI, Inc. | 13/436,259 | 3/30/2012 | Consolidated Presentation Of Pharmaceutical Information From Multiple Sources | US |
| JS Genetics Inc. | 13/266434 | 4/28/2010 | Molecular Diagnosis of Fragile X Syndrome Associated with FMR1 Gene | US |
| JS Genetics Inc. | 13/266429 | 4/26/2010 | Method of Prenatal Molecular Diagnosis of Down Syndrome and Other Trisomic Disorders | US |

Foreign Cases:


| Owner | App. No. Patent No. | Filing Date Issue Date | Title | Country |
|-----------------------|------------------------|---------------------------|---|---------|
| Interpace Diagnostics | PCT/US07/78936 NA | 09/19/2007 NA | MicroRNAs Differentially Expressed in Pancreatic Disease and Uses Thereof | PCT |
| Interpace Diagnostics | 2007299828 NA | 9/19/2007 NA | MicroRNAs Differentially Expressed in Pancreatic Disease and Uses Thereof | AU |
| Interpace Diagnostics | 2,664,383 NA | 9/19/2007 NA | MicroRNAs Differentially Expressed in Pancreatic Disease and Uses Thereof | CA |
| Interpace Diagnostics | 12159733 NA | 9/19/2007 NA | MicroRNAs Differentially Expressed in Pancreatic Disease and Uses Thereof | EU |
| Interpace | 2009-529373 | 9/19/2007 | MicroRNAs Differentially Expressed in | JP |



| Owner | App. No. Patent No. | Filing Date Issue Date | Title | Country |
|--------------------------|-------------------------|---------------------------|---|---------|
| Diagnostics | 5520605 | 4/11/2014 | Pancreatic Disease and Uses Thereof | |
| Interpace Diagnostics | PCT/US11/61237 NA | 11/17/2011 NA | MiRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms | PCT |
| Interpace Diagnostics | 2011329772 NA | 11/17/2011 NA | MiRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms | AU |
| Interpace Diagnostics | 1120130122650 NA | 11/17/2011 NA | MiRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms | BR |
| Interpace Diagnostics | 2817882 NA | 11/17/2011 NA | MiRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms | CA |
| Interpace Diagnostics | 14150739.2 NA | 11/17/2011 NA | MiRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms | EU |
| Interpace Diagnostics | 226356 NA | 11/17/2011 NA | MiRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms | IL |
| Interpace Diagnostics | 2013540026 NA | 11/17/2011 NA | MiRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms | JP |
| Interpace Diagnostics | PCT/US2012/062330 NA | 10/27/2012 NA | miRNAs as Diagnostic Biomarkers to Distinguish Benign from Malignant Thyroid Tumors | PCT |
| Interpace Diagnostics | 12787991.4 NA | 10/27/2012 NA | miRNAs as Diagnostic Biomarkers to Distinguish Benign from Malignant Thyroid Tumors | EU |
| Interpace Diagnostics | PCT/US2013/030990 NA | 3/13/2013 NA | Diagnostic mirnas for Differential Diagnosis of Incidental Pancreatic Cystic Lesions | PCT |
| PDI, Inc. | PCT/US2013/034670 | 3/29/2013 | Consolidated Presentation Of Pharmaceutical Information From Multiple Sources | PCT |

Co-owned Patent Applications

| Owner | App. No. Patent No. | Filing Date Issue Date | Title | Country |
|--|-------------------------|---------------------------|---|---------|
| Interpace Diagnostics & Brigham Women's Hospital | 13/801,737 NA | 3/13/2013 NA | Diagnostic Mirnas For Differential Diagnosis Of Incidental Pancreatic Cystic Lesions | US |
| Interpace Diagnostics & Brigham Women's Hospital | PCT/US2013/030990 NA | 3/13/2013 NA | Diagnostic Mirnas For Differential Diagnosis Of Incidental Pancreatic Cystic Lesions | PCT |

Trademarks

| Owner | Mark | Country | App. No. Reg. No. |
|----------------------------------|---|---------|-------------------------|
| Interpace Diagnostics | MIRINFORM | US | 77/447,187 3,546,361 |
| Interpace Diagnostics | MIRINFORM | US | 85/067,844 4,071,426 |
| Interpace Diagnostics | MIRINFORM | US | 85/067,850 4,071,427 |
| Interpace Diagnostics | MIRINFORM | MP (CN) | A0035669 1162299 |
| Interpace Diagnostics | MIRINFORM | MP (CN) | A0035671 11621785 |
| Group DCA, LLC | DIAGRAM | US | 85/145,671 3,970,284 |
| Group DCA, LLC | CUECARD | US | 78/826,562 3,486,366 |
| Group DCA, LLC | PD ONE | US | 85/567,143 4,593,300 |
| Group DCA, LLC | PD ONE | US | 85/567,130 4,593,299 |
| Interpace Diagnostics, LLC | BaraGen | US | 86/390,390 n/a |
| Interpace Diagnostics, LLC | THYMIRA | US | 86/370,332 n/a |
| Interpace Diagnostics, LLC | THYRAMIR | US | 86/370,328 n/a |
| Interpace Diagnostics, LLC | PancraGEN | US | 86/370,325 n/a |
| Interpace Diagnostics, LLC | ThyGenX | US | 86/365,003 n/a |
| Interpace Diagnostics, LLC | PANCRAMIR | US | 86/357,914 n/a |
| Interpace Diagnostics LLC |  | US | 86/290,079 n/a |
| Interpace | POWER IN | US | 86/325,980 |

| Owner | Mark | Country | App. No. Reg. No. |
|-----------------|---|---------|-------------------------|
| Diagnostics LLC | PERFORMANCE | | n/a |
| PDI, Inc. | INTERPACE DIAGNOSTICS | US | 86/130,866 n/a |
| PDI, Inc. |  | US | 76/630,045 3,617,915 |
| PDI, Inc. |  | US | 76/630,047 3,344,703 |
| PDI, Inc. | PDI | US | 76/630,046 3,617,916 |
| PDI, Inc. | PD ONE REP | US | 86/227,209 n/a |
| PDI, Inc. | THE MEDICAL BUZZ | US | 85/930,489 4465320 |
| PDI, Inc. | THE MEDICAL BAG | US | 85/929,050 n/a |
| PDI, Inc. | WHAT KILLED 'EM | US | 85/930,510 4,465,321 |
| PDI, Inc. | DESPICABLE DOCTORS | US | 85/930,412 4465315 |
| PDI, Inc. | COMIC SEIZURE | US | 85/930,420 4465316 |
| PDI, Inc. | HCP ECOSYSTEM | US | 85/971374 n/a |
| PDI, Inc. | INTERPACE DIAGNOSTICS | US | 86/130866 |

Mask Works

none